Title: YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.
Journal: PloS one 20170101
Title: Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.
Journal: Molecular oncology 20140501
Title: Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20130827
Title: Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
Journal: The Journal of pharmacology and experimental therapeutics 20121001
Title: Survivin is a therapeutic target in Merkel cell carcinoma.
Journal: Science translational medicine 20120509
Title: The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Journal: Anticancer research 20120501
Title: A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120401
Title: Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Journal: Molecular cancer therapeutics 20120101
Title: Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
Journal: Biochemical pharmacology 20111101
Title: YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Journal: International journal of oncology 20110901
Title: Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Journal: Anti-cancer drugs 20110601
Title: Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.
Journal: PloS one 20110101
Title: Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Journal: British journal of cancer 20100629
Title: Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100101
Title: Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090601
Title: Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090301
Title: Survivin expression in primary malignant melanoma of the esophagus.
Journal: Scandinavian journal of gastroenterology 20090101
Title: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110
Title: Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma.
Journal: Biomedical chromatography : BMC 20080701
Title: Nakahara T, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014-21.
Title: Iisa T, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496-504.
Title: Guo K, et al. A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137-47.
